TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

TME Pharma N.V.

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results.NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

COM:TMEPHARMA